Skip to content
value.today

Roivant Sciences Ltd.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to salesPrice to sales of Biotechnology: $19 M to $83 M, median $41 MPrice to bookPrice to book of Biotechnology: $14.0 B to $55.8 B, median $20.6 B$0 M$15.1 B$30.1 B$45.2 B$60.3 BMarket value $26.1 B

Your own DCF model

A full discounted-cash-flow model of Roivant Sciences Ltd., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Biotechnology

Multiples of its companies with a market value at most 60 days old, times Roivant Sciences Ltd.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Roivant Sciences Ltd.Applied toValue (25th to 75th)Companies
Price to sales2.2× / 5.0× / 10.1×—revenue $8 M$19 M to $83 M85
Price to book3.1× / 4.5× / 12.3×5.8×book equity $4.5 B$14.0 B to $55.8 B70

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Roivant Sciences Ltd.'s multiples at each month end with a market cap on file, Jan 2024 to Oct 2026, each against its own median.

Price to sales

786.2×

Now above its median of 278.4×, in the top quarter of its range; range 223.4× to 786.2× over 16 months.

0×197×393×590×786×20252026Price to sales 786×Median 278×

Price to book

5.8×

Now above its median of 2.9×, in the top quarter of its range; range 1.3× to 7.5× over 24 months.

0×2×4×6×8×20252026Price to book 6×Median 3×

as of Oct 27, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 27, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Mar 31, 2026$8 M$-300 M$-750 M$8 M$-759 M—SEC annual report (10-K, 20-F)
FY2024to Mar 31, 2025$29 M$-172 M$-839 M$5 M$-844 M—SEC annual report (10-K, 20-F)
FY2023to Mar 31, 2024$33 M$4.3 B$-765 M$1 M$-767 M$-6.1 BSEC annual report (10-K, 20-F)
FY2022to Mar 31, 2023$32 M$-1.0 B$-843 M$13 M$-856 M$-1.3 BSEC annual report (10-K, 20-F)
FY2021to Mar 31, 2022$55 M$-845 M$-678 M$17 M$-695 M$-1.9 BSEC annual report (10-K, 20-F)
FY2020to Mar 31, 2021$24 M$-809 M$-552 M$6 M$-558 M$-1.9 BSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $26.1 B on Oct 27, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.